Bivalent vaccine effectiveness against type-specific HPV positivity: evidence for cross-protection against oncogenic types among Dutch STI clinic visitors

Medical Microbiological Laboratories, and the Public Health Services, D. Adema, R. Buist-Arkema, A. Beerens, D. Luijt, S. Meijer, J. Schirm, M. Peeters, J. Rossen, H. Verbakel, P. Van Esch, J. Verweij, A. Van Der Eijk, R. Huisman, C. Kerkhof, H. Korff, M. Schutten, J. Velzing, F. Verduyn-Lunel, S. LakbiachP. Van Rosmalen, R. Schuurman, D. Abma, K. Adams, S. Bruisten, I. Linde, P. Oostvogel, C. Touwen, W. Vermeulen, A. Brink, J. Nelissen, P. Wolffs, N. Duijvendijk, P. Schneeberger, M. D. Innissen Van Poppel, W. Melchers, Y. Poort, M. Hooghiemstra, H. Huisman, J. Weel, F. Bosma, F. Geeraedts, I. Polman, P. van Goor, M. Wolfhagen, C. de Mooij, E. Van Koolwijk, M. Peters, C. Swanink, R. Tiemessen, T. Van Zwet, J. Janssen, M. Pelsers, W. de Waal, G. Aalfs, J. Kiewiet, P. Sanders, H. Van Buel-Bruins, C. Van Bokhoven-Rombouts, P. Cornelissen, M. Kersten, C. Van Ruitenbeek, I. Molenaar, E. Doorn, L. Masthoff, E. Pannekoek, V. Sigurdsson, M. Bugter, H. Götz, M. Illidge-Onder de Linden, M. Mattijssen, J. Stam, E. Swaders, F. De Groot, F. Postma, E. Brouwers, A. Niekamp, M. Smit, A. Botraby, D. Bukasa, C. De Haan, P. Hut-van Vliet, T. Taconis, M. De Graas, I. Hondelink, C. Kampman, A. Gelissen-Hansen, I. De Koning, H. Van Kruchten, M. Van De Pas, H. Fennema, T. Heijman, A. Hogewoning, A. Van Leeuwen, M. Van Rooijen, F. Neienhuijsen, M. Pelgrim

Research output: Contribution to journalArticleAcademicpeer-review

66 Citations (Scopus)

Abstract

Background: Observational post-marketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and non-vaccine types in a high-risk population.

Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a PCR-based assay (SPF10-LiPA25) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-reported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by a logistic mixed model.

Results: We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled VE against HPV-16/18 was 89.9% (81.7-94.4). Moreover, we calculated significant VE against non-vaccine types HPV-45 (91%), HPV-35 (57%), HPV-31 (50%) and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated similar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination <5 years ago (83% and 33% respectively).

Conclusion: We demonstrated high VE of the bivalent vaccine against HPV-16/18 and cross-protection against HPV-45/35/31/52. Protection against HPV-16/18 was sustained up to six years post-vaccination.

Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalJournal of infectious diseases
Volume217
Issue number2
Early online date11 Nov 2017
DOIs
Publication statusPublished - 15 Jan 2018

Keywords

  • Journal Article

Cite this